Please note: I have added further clarification and correction to the Baker, et. al. paper. I overlooked that the paper does indicate a large difference in binding affinity and electrostatic potential between the Ad26 (J&J) as well as ChAdOx1 (AstraZeneca), so please keep in mind that although the researchers argue that binding to Adenoviral vectors by PF4 may be occurring, the extent to which it is occurring in Ad26 viral vectors should be questioned. Apologies for overlooking this error.
May 13, 2022·edited May 13, 2022Liked by Modern Discontent
Fantastic.
I have wanted to put a vector post together but my research was far less productive. There’s also very little info on what has been verified rather than assumed as far as the physical structure and in vivo behavior of the main two products.
AZ is two doses, spaced a weird amount of weeks apart. https://www.bmj.com/content/372/bmj.n421 refers to the normal 3 being adjusted to 12 during the UK rollout so I think 3 is the manufacturer's norm. E1 is knocked out, and it’s unclear to what degree this affects expression of other structural proteins. But presumably spike is still expressed, otherwise no antibodies. Except once again I’m reluctant to say this for sure, because what if there’s just leftover spike in the injection. Again, there’s no apparent lit from the manufacturers on this question.
Thank you! I am grateful for your ability to present complex biochemical patterns into a readable, educational, and rewarding experience. There is so much more going on than meets the eye, and I remain curious.
Unintended consequences such as blood clotting are why vaccines typically are developed over a span of years, rather than the span of months for the SARS-CoV-2 inoculations, courtesy of Operation Warp Speed.
Speed and safety are mutually exclusive in most things, and so the accelerated pace of Operation Warp Speed necessarily entailed a sacrifice in the safety of the resulting inoculations. There simply was not time allotted to investigate these potential adverse effects early in clinical trials.
Of course, the crowning indignity of that sacrifice is that it did not result in an effective vaccine that stopped community spread of the virus--the promise that was hyped by Big Pharma, government, and the media.
Please note: I have added further clarification and correction to the Baker, et. al. paper. I overlooked that the paper does indicate a large difference in binding affinity and electrostatic potential between the Ad26 (J&J) as well as ChAdOx1 (AstraZeneca), so please keep in mind that although the researchers argue that binding to Adenoviral vectors by PF4 may be occurring, the extent to which it is occurring in Ad26 viral vectors should be questioned. Apologies for overlooking this error.
Fantastic.
I have wanted to put a vector post together but my research was far less productive. There’s also very little info on what has been verified rather than assumed as far as the physical structure and in vivo behavior of the main two products.
AZ is two doses, spaced a weird amount of weeks apart. https://www.bmj.com/content/372/bmj.n421 refers to the normal 3 being adjusted to 12 during the UK rollout so I think 3 is the manufacturer's norm. E1 is knocked out, and it’s unclear to what degree this affects expression of other structural proteins. But presumably spike is still expressed, otherwise no antibodies. Except once again I’m reluctant to say this for sure, because what if there’s just leftover spike in the injection. Again, there’s no apparent lit from the manufacturers on this question.
I think JJ is same gene knocked out, let me check. Doorlesscarp also did a resource hub for the vectors here https://doorlesscarp953.substack.com/p/adenovirus-hepatitis-in-children
Thank you! I am grateful for your ability to present complex biochemical patterns into a readable, educational, and rewarding experience. There is so much more going on than meets the eye, and I remain curious.
Aloha
Unintended consequences such as blood clotting are why vaccines typically are developed over a span of years, rather than the span of months for the SARS-CoV-2 inoculations, courtesy of Operation Warp Speed.
Speed and safety are mutually exclusive in most things, and so the accelerated pace of Operation Warp Speed necessarily entailed a sacrifice in the safety of the resulting inoculations. There simply was not time allotted to investigate these potential adverse effects early in clinical trials.
Of course, the crowning indignity of that sacrifice is that it did not result in an effective vaccine that stopped community spread of the virus--the promise that was hyped by Big Pharma, government, and the media.
"So, Iet's say
you want to change
the human body."
"You want to fix a mistake."
"You want to repair something,
improve something."
"Well, if you're going
to reprogram human
genetic materiaI,
you need a deIivery
system, and nothing
works better than virus."
"It's Iike a suitcase."
"You pack in genetic mutation,
infect the body
and the vector unIoads
into the target cells."
"But getting it
where you want it,
how you want it,
is the nightmare."